AI models analyzing routine H&E slides can identify genomic alterations and immune patterns in NSCLC, supporting biomarker discovery and patient stratification, according to studies to be presented by Lunit at WCLC 2026.
Kumamoto University researchers have developed a blood test that analyzes nucleosome structures in cell-free DNA to detect breast cancer recurrence.
The FDA has cleared Roche's Elecsys pTau217 blood test to aid in identifying Alzheimer disease amyloid pathology, marking the first single-biomarker assay for both rule-in and rule-out use on existing lab instruments.
The FDA has expanded approval of Roche’s PATHWAY HER2 and VENTANA HER2 tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma, aiding selection of patients for HER2-targeted therapy.
Labcorp has introduced hepatitis D reflex testing, enabling automatic screening for hepatitis D in patients who test positive for hepatitis B surface antigen, aiming to address underdiagnosis.
A multi-site study found cfDNA screening achieves 94.4% sensitivity for fetal risk assessment without partner testing, supporting its routine use in general-risk pregnancies.
A new ultrasensitive blood test may detect Sjögren’s disease more than 10 years before symptoms appear by identifying chronically elevated interferon alpha levels in patient blood samples.
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
Seed Healthcare has led a strategic investment in Diadem to support US commercialization of AlzoSure Predict, a blood-based Alzheimer’s diagnostic recently validated in over 900 patients and designated a Breakthrough Device by the FDA.
A University of Exeter study finds that adding a genetic risk score to MODY testing can identify hidden type 1 diabetes in 16% of patients with negative genetic results, supporting updated NHS diagnostic protocols.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.